| 2009 | Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2023 | Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
| ESMO OPEN |
| 2014 | Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR | ONCOLOGIST |
| 2022 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
| LUNG CANCER |
| 2013 | Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer | LUNG CANCER |
| 2006 | Phase II Study of Cisplatin Combined with Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma | PANCREATOLOGY |
| 2012 | Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer | ANTICANCER RESEARCH |
| 2008 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
| ANNALS OF ONCOLOGY |
| 2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2022 | Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer | INTERNATIONAL JOURNAL OF CANCER |
| 2007 | Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib | JOURNAL OF CLINICAL ONCOLOGY |
| 2006 | Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2015 | Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10 | GYNECOLOGIC ONCOLOGY |
| 2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2022 | Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH) | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer | ANNALS OF ONCOLOGY |
| 2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2022 | Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2011 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer
| INVESTIGATIONAL NEW DRUGS |
